BMO raises Abbvie stock price target to $300 on Skyrizi strength

BMO Capital raised AbbVie’s price target to $300 from $258 (about 21% upside from ~$248) while keeping an Outperform rating, citing continued revenue durability for Skyrizi through Q2 2026. BMO said physician/patient preference drivers—superior efficacy, an extended injectable dosing interval, and secondary approval in psoriatic arthritis—should support demand, though competition from Icotyde remains early and oral-use debate/adherence risks persist. Separately, the European Commission granted marketing authorization for Tepkinly in combination therapy for relapsed/refractory follicular lymphoma, reinforcing AbbVie’s expanding pipeline.

Analysis

The real signal here is not the target raise; it is confirmation that ABBV’s immunology franchise is becoming more durable than the market models usually assume. In chronic inflammatory disease, adherence and dosing convenience often matter more than headline efficacy after the first script, so a longer interval injectable with expanding label coverage can defend share even when a new oral entrant gets initial attention. That supports a higher quality multiple, but the stock is already close to peak sentiment, so the next leg likely requires clean earnings revisions rather than another broker upgrade.

AMGN is the cleaner relative loser because the competitive risk sits in the patient-flow layer, not just in direct prescriptions. If oral therapies continue to face persistence problems, payer preference should still favor the more durable biologic pathway, which limits the upside from a new launch. The key second-order risk is not immediate erosion; it is that a successful later-year data read could trigger formulary re-ranking and make AMGN’s oral franchise a slower-growth asset over 6-18 months.

The oil/geopolitical backdrop matters mostly as a cross-asset factor: sustained crude volatility would tend to support defensives like healthcare versus consumer/cyclicals, but it does not change the drug-level thesis. Contrarian view: the market may be underpricing payer pushback and step-therapy rules, which can blunt ABBV’s share gains even when physician preference is strong. The thesis is falsified if upcoming earnings or label/data updates show slower-than-expected immunology growth, or if the new oral competitor gains secondary PsA positioning and clean persistence data.

Key Decisions for Investors

• Go long ABBV on any 2-4% pullback over the next 1-3 weeks; target another 5-8% over 1-3 months if Skyrizi growth and guidance stay intact. Falsify on a guide-down, slower immunology sell-through, or pricing pressure in the quarter.
• Enter a pair trade: long ABBV / short AMGN for 1-3 months into the next clinical/data cycle. Thesis is durable injectable persistence vs. oral adherence risk; expected spread move 4-6%. Cover if late-year PsA data shows the oral competitor can drive formulary wins.
• If already long AMGN, hedge with a temporary ABBV call overlay rather than outright selling the name. This keeps exposure to the broader healthcare bid while reducing competitive read-through risk into the next catalyst window.
• Do not chase TGT or broad consumer cyclicals off this article; the only actionable macro read-through is a mild defensive tilt if crude volatility persists, which is a sector allocation issue rather than a single-name trade.